Twist Bioscience Corporation (TWST) Actualités

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation...

Twist Bioscience Launches FlexPrep™ Ultra-High Throughput Library Preparation Kit for Applications in Agrigenomics and Population Genomics

Normalization by Ligation™ library preparation technology processes thousands of samples at low cost with enhanced multiplexing and novel...

Form 4 - Statement of changes in beneficial ownership of securities

Twist Bioscience to Report Fiscal 2024 Fourth Quarter and Full Year Financial Results on Monday, November 18, 2024

Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its...

Form 144 - Report of proposed sale of securities

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

Twist to retain all upfront, service and other revenue earned under antibody discovery and biopharma solutions agreements as well as half of...

Form 8-K - Current report

Twist Bioscience Appoints Mike Fero, Ph.D., as Chief Information Officer

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities